Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Articles
  3. preclinical services for pancreatic cancer
Show results for
News

Refine by
Date

  • Older

Preclinical Services For Pancreatic Cancer Articles & Analysis

4 articles found

Alfa Cytology Launches Innovative Bladder Cancer Therapeutic Antibody Development Services

Alfa Cytology Launches Innovative Bladder Cancer Therapeutic Antibody Development Services

Alfa Cytology has unveiled new services focused on therapeutic antibody development for bladder cancer research.Alfa Cytology, a prominent cancer research services supplier based in New York, proudly announces the launch of its comprehensive services for bladder cancer therapeutic antibody ...

ByAlfa Cytology


   Innovative Labs Rolls Out Enhanced Centrosome Research Tools for Cancer Studies

Innovative Labs Rolls Out Enhanced Centrosome Research Tools for Cancer Studies

CD BioSciences, a biotech company specializing in centrosomal study, has recently launched new services for anti-centrosome antibody development. The services help identify and track centrosomes in experiments, demonstrating the strength of anti-centrosome antibodies as a great tool for centrosome research. The centrosome is a key cellular structure that plays a crucial role in the organization ...

ByCDBioSciences - VLPlant


Small Molecule Drug Development at Alfa Cytology: Transforming Cancer Research

Small Molecule Drug Development at Alfa Cytology: Transforming Cancer Research

Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research. Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. The services tend to accelerate the discovery and optimization of molecule drugs with a strict quality control system. Small molecule drugs ...

ByAlfa Cytology


An Emerging Aim: ADC Target Protein - Nectin-4

An Emerging Aim: ADC Target Protein - Nectin-4

The biologics license application (BLA) has been accepted for Enfortumab Vedotin for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have previously received PD-1/PD-L1 inhibitors and platinum-containing chemotherapy. Enfortumab Vedotin is the first domestically submitted targeted antibody-drug conjugate that specifically targets Nectin-4. Enfortumab ...

ByBeta Lifescience

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT